Randall Snook, MD
Internal Medicine · Lone Tree, CONPI 1558417659
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 882 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 60 manufacturers reported payments, led by AbbVie at 24.2% of the total. Reporting peaked in 2021 at $2,826 and has fallen 50.9% since, to $1,388 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 882 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$1K
- Novo Nordisk$1K
- Pfizer$812
- Lilly USA, LLC$707
- Amgen$511
- plus $7K from 54 others
What the payments were for
- Food & beverage$14,642100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,660 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $82,007 |
| MounjaroTirzepatide | 66 | $76,102 |
| EliquisApixaban | 57 | $50,376 |
| XareltoRivaroxaban | 37 | $43,952 |
| OzempicSemaglutide | 42 | $40,053 |
| JanuviaSitagliptin Phosphate | 22 | $26,738 |
| FarxigaDapagliflozin Propanediol | 14 | $25,088 |
| Repatha SureclickEvolocumab | 14 | $8,087 |
| SynthroidLevothyroxine Sodium | 102 | $6,652 |
| TirosintLevothyroxine Sodium | 17 | $5,110 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $2,019 |
| Testosterone Cypionate | 26 | $2,001 |
| Liothyronine Sodium | 61 | $1,931 |
| Atorvastatin Calcium | 217 | $1,818 |
| Levothyroxine Sodium | 257 | $1,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $213 | $82,00761 claims |
| Lilly USA, LLCMounjaro | $707 | $76,10266 claims |
| PfizerEliquis | $812 | $50,37657 claims |
| Johnson & JohnsonXarelto | $408 | $43,95237 claims |
| Novo NordiskOzempic | $1,077 | $40,05342 claims |
| MerckJanuvia | $258 | $26,73822 claims |
| AstraZenecaFarxiga | $1,327 | $25,08814 claims |
| AbbVieSynthroid | $3,542 | $6,652102 claims |
| IBSA Pharma Inc.Tirosint | $238 | $5,11017 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $395 | $3,312276 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Lone Tree
- Andrzej DankowskiLone Tree$9K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
- Luke WebbColorado Springs$287K
- Samuel PiedadColorado Springs$154K
- Sophia AmbrusoLittleton$62K
- Kristine KuhnAurora$61K
- Kenneth OleszekDenver$60K
- Munni SelagamsettyColorado Springs$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.